

PUBLISHED INFORMATION REQUEST

Reference: 13171
Description: Patient Treatment and Migraine

Response

Q1. Please provide the number of patients treated (for any condition) in the last 4 months with:
Ajovy (fremanezumab) - **0**
Aimovig (erenumab) - **0**
Emgality (galcanezumab) - **0**

Q2. How many of these patients were treated as part of a free or nominal charge scheme with:
Ajovy (fremanezumab) - **0**
Aimovig (erenumab) - **0**
Emgality (galcanezumab) - **0**

Q3. How many patients have you treated in the last 4 months for:
Data period 1 July 2020 – 31 October 2020

Any type of migraine

222 patients with Migraine diagnosis admitted in the 4 month period. It is not possible to ascertain if any of the medications dispensed were specifically for the treatment of migraine. Also details of medicines given from ward stock which may have been used in the treatment of migraine are not available from the pharmacy dispensing system.

Chronic migraine (15+ headache days per month).

The Trust does not hold this information

Episodic migraine (4+ headache days per month)

The Trust does not hold this information

Q4. Please provide the number of migraine patients treated in the last 4 months with Botulinum Toxin (i.e. Botox, Dysport, Xeomin).
Zero

Q5. In case you do not treat chronic or episodic migraine, can you please tell us which hospital or trust you refer these patients to?

The neurology service is a visiting service from the Lancashire Teaching Hospital Foundation Trust (LTH) and therefore any queries regarding specifics of treatment would need to be directed towards them.

You can contact LTH as follows: <https://www.lancsteachinghospitals.nhs.uk/freedom-of-information/>

Trust Headquarters:
Westmorland General Hospital
Burton Road
Kendal
LA9 7RG
Tel: 01539 716621

CHAIR: PROFESSOR MIKE THOMAS
CHIEF EXECUTIVE: AARON CUMMINS